The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients
The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients
复制标题
DOI：
10.1016/j.lungcan.2009.02.020
复制
发表时间：
2009-12-01
期刊：
影响因子：
5.3
通讯作者：
Szemraj, Janusz
中科院分区：
文献类型：
--
作者：
Bieniasz, Magdalena;Oszajca, Katarzyna;Szemraj, Janusz
肺癌是肿瘤学中的一个特殊挑战。全世界每年发生100多万新病例，尽管有许多临床试验和现代诊断技术，但长期存活率仅略有提高。目前研究的目的是探索新的分子预后因素和确定新的抗癌治疗靶点。目前的证据表明，血管生成是由几种血管生成因子控制的，包括VEGF和BMP-2。研究还表明，VEGF在这一过程中起着关键作用，而这一过程对癌变至关重要。我们的研究表明，肺癌样本中VEGF、BMP-2和BMP-4 mrna的表达明显高于邻近正常肺组织（实时RT-PCR），分别为7.1倍、25.6倍和2.3倍。Pearson相关系数分析显示VEGF与BMP-2基因表达呈正相关，而VEGF与BMP-4基因表达无显著相关。血清VEGF水平的平均标准差为423 +/- 136 pg/ml。T1肿瘤患者与T2、T3、T4肿瘤患者血清VEGF水平差异有统计学意义。T2、T3和T4肿瘤患者血清VEGF水平分别比T1肿瘤患者高1.6倍、1.8倍和2.3倍。在目前的研究中，+936C/T VEGF基因多态性的936T等位基因纯合子患者的VEGF基因表达比936C等位基因纯合子患者低12倍，血清VEGF水平低1.3倍。总之，我们的研究结果强调了VEGF和BMP-2这两种血管生成因子以及+936C/T VEGF基因多态性在肺癌患者评估中的重要性。2009爱思唯尔爱尔兰有限公司版权所有。
Lung cancer is a particular challenge in oncology. More than 1 million new cases occur worldwide every year and despite many clinical trials and modern diagnostic techniques, long-term survival rate has only marginally improved. The aim of the current research is to explore new molecular prognostic factors and identify new targets for anticancer therapy. Current evidence shows that angiogenesis is controlled by several angiogenic factors including VEGF and BMP-2. It has been also demonstrated that VEGF plays a key role in this process that is essential in carcinogenesis. Our study has shown that the expressions of the VEGF, BMP-2 and BMP-4 mRNAs were significantly higher (7.1-fold, 25.6-fold and 2.3-fold, respectively) in lung cancer samples than in adjacent normal lung tissues (real-time RT-PCR). Analysis based on the Pearson's correlation coefficient indicated the positive correlation between VEGF and BMP-2 gene expression, whereas no significant correlation between VEGF and BMP-4 gene expression was found. The mean standard deviation serum level of VEGF was 423 +/- 136 pg/ml. Significant differences in the serum levels of VEGF between patients with T1 tumors and patients with T2, T3 or T4 tumors were observed. Patients with T2, T3 and T4 tumors, respectively, had 1.6-fold, 1.8-fold and 2.3-fold greater serum levels of VEGF than their peers with T1 tumors. In current study patients homozygous for the 936T allele of the +936C/T VEGF gene polymorphism had 12-fold lower VEGF gene expression and 1.3-fold lower VEGF serum level than patients homozygous for the 936C allele. In conclusion, our findings underline the importance of the two angiogenic factors namely VEGF and BMP-2 as well as +936C/T VEGF gene polymorphism in the evaluation of lung cancer patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.